BCC is new territory for cancer immunotherapies however, and Libtayo is the first drug in the PD-1/PD-L1 inhibitor class to get go-ahead in this common form of skin cancer. It's been cleared for ...

Sanofi and Regeneron plan to file their cancer immunotherapy Libtayo (cemiplimab) in a new indication following supportive findings from a phase 2 trial in a hard to treat group of skin cancer ...

Eighteen presentations will share the latest insights from ongoing research of approved and investigational treatment regimens across a range of difficult-to-treat cancers including non-melanoma ...

They pointed to "dramatically improved" survival outcomes with immunotherapy, and objective response rates of 44% to 60% with ...

including non-melanoma skin cancer, lung cancer, lymphoma, and multiple myeloma. Key topics include results from the Phase 3 trial of Libtayo for high-risk cutaneous squamous cell carcinoma and ...

Libtayo reached $367M in Q4 global sales, up 50% year-over-year, supported by gains in lung cancer and non-melanoma skin ...

A study in Nature Communications found that older cancer patients have similar outcomes with immune checkpoint inhibitors as ...

The company will share 18 presentations on research into treatment regimens for various cancers, including non-melanoma and melanoma skin cancers ... of PD-1 inhibitor Libtayo in high-risk ...